Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the back of lower sales and multiple one offs.

Total revenue from operations of the Hyderabad-headquartered generic drugmaker was lower at ₹7,546.4 crore (₹8,528.4 crore), according to the results prepared as per Indian Accounting Standards (Ind AS).

The company said the results include the adverse impact of a Shelf Stock Adjustment (SSA) related to lenalidomide (generic of cancer drug Revlimid) of ₹453 crore, impairment of CAR-T assets and Eftilagimod Alfa of a total of ₹227.7 crore, provisions related to VAT liability of ₹114.1 crore during the quarter.

On the SSA, the company said it recorded ₹453 crore as a reduction of revenue from sale of goods in its Global Generics Segment.

For the fiscal ended March, Dr. Reddy’s consolidated net profit declined to ₹4,157.6 crore (₹5,725.2 crore). Total revenue from operations rose to ₹33,700 crore (₹32,643.9 crore).

The company said FY26 results includes adverse impact of VAT liability provision of ₹69.5 crore and New Labour Codes of ₹117 crore.

“Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimisation,” Co-Chairman and MD G.V. Prasad said.

The company has declared a final dividend of ₹8 per equity share (face value of ₹1 each) for FY26.